Telik (TELK) Resumes Trading, Up 73%
Tweet
Share
E-mailGet Alerts TELK Hot Sheet
Join SI Premium – FREE
Telik Inc. (NASDAQ: TELK) has resumed trading following the volatility trading halt and is now up 73% to $2.51. The company was granted orphan drug status for Telintra for myelodysplastic syndrome.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) halted, news pending
- This Swiss stock offers "best buying opportunity in a while": Barclays
- SAP Q2 earnings preview: Analysts flag key risks and potential tailwinds
Create E-mail Alert Related Categories
Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
